ANTI-HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN B1 (ANTI-RA33) ANTIBODIES IN RHEUMATOID ARTHRITIS AND SYSTEMIC SCLEROSIS

Anti-heterogeneous nuclear ribonucleoprotein (RNP) autoantibodies (AAbs) are encountered in many autoimmune rheumatic diseases (ARDs). The potential diagnostic value of the RA33 AAb complex consisting of RNP A2 and alternative domains of the splicing proteins RNP B1 and RNP B2 is now of interest to rheumatologists. Subjects and methods. The authors studied the frequency of anti-RNP B1 AAbs in 300 patients with systemic ARDs, including those with rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and Sjö gren's syndrome (SS) and in 53 people without ARDs, who constituted a control group. Serum anti-RNP B1 AAbs were assessed by enzyme immunoassay. Results and discussion. The frequency of anti-RNP B1 AAbs in patients with ARDs was much higher than that in the control group: 170/300 (56.6%) and 8/53 (13%) patients, respectively. Anti-RNP B1 AAbs were detected in 78.5% (113/144) of the patients with RA; 40.3% (23/57) of those with AS, in 67.5% (27/40) of those with SSc, in 36.4% (16/44) of those with SLE, and in 13.3% (2/15) of those with SS. The diagnostic sensitivity of the marker for RA was 78.5%, its diagnostic specificity was 84.9%; the likelihood ratio of positive and negative results was 5.24 and 0.24, respectively. In the patients with RA, the level of anti-RNP B1 AAbs significantly correlated with that of C-reactive protein and erythrocyte sedimentation rate, while in those with SSc the detection of anti-RNP B1 AAbs was related to the rigidity of the vascular wall and the presence of hypertension. The frequency of anti-RNP B1 AAbs among the RA patients seronegative for rheumatoid factor and anti-cyclic citrullinated peptide antibodies was 15.4%. Conclusion. Anti-RNP B1 AAs are a useful laboratory marker (with the upper limit of the normal range being 3.3 U/ml), but are of limited value in the diagnosis of RA. Anti-RNP B1 AAbs may be regarded as an additional diagnostic marker for RA.

RA33, anti-RNP B1 autoantibodies, systemic sclerosis, rheumatoid arthritis

1. Krecic AM, Swanson MS. HnRNP complexes: composition, structure, and function. Curr Opin Cell Biol. 1999;11(3):363-71. doi: 10.1016/S0955-0674(99)80051-9

2. Swanson MS. Functions of nuclear pre-mRNA/mRNA binding proteins. In: Lamond AI, editor. Pre-mRNA Processing. Berlin, Heidelberg: Landes Co Springer Verlag; 1995. P. 17-33.

3. Maslyanskiy AL, Olinek PA, Lapin SV, et al. Anti-hnRNP B1 (RA33) autoantibodies are associated with the clinical phenotype in russian patients with rheumatoid arthritis and systemic sclerosis. J Immunol. 2014;2014:Article ID 51659. doi: 10.1155/2014/516593

4. Олейник ПА, Маслянский АЛ, Лапин СВ и др. Антитела к HnRNP (RA33) у больных с ревматоидный артритом. Медицинский академический журнал. 2014;14(3):59-66 [Oleinik PA, Maslyanskiy AL, Lapin SV, et al. Anti-HNRNP (RA33) antibody in rheumatoid arthritis. Meditsinskii Akademicheskii Zhurnal. 2014;14(3):59-66 (In Russ.)].

5. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology. European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2011;69:1580-8. doi: 10.1136/ard.2010.138461

6. Meyer O, Tauxe F, Fabregas D, et al. Anti-RA33 antinuclear antibody in rheumatoid arthritis and mixed connective tissue disease: comparison with antikeratin and antiperinuclear antibodies. Clin Exp Rheumatol. 1993;11:473-8.

7. Лапин СВ, Маслянский АЛ. Лабораторная диагностика ревматоидного артрита. Новые перспективы. Клинико-лабораторный консилиум. 2009;1(26):69-74 [Lapin SV, Maslyansky AL. Laboratory diagnosis of rheumatoid arthritis: new perspectives. Kliniko-Laboratornyi Konsilium. 2009;1(26):69-74 (In Russ.)].

8. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984 Apr;27(4):361. doi: 10.1002/art.1780270401

9. American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis. Arthritis Care Res. 2012 Jun;64(6):797-808. doi: 10.1002/acr.21664

10. Masi AT, Rodnan GP, Medsger TA, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581-90. doi: 10.1002/art.1780230510 11. Васильев ВИ, Симонова МВ, Сафонова ТН. Критерии диагноза болезни и синдрома Шегрена. В кн.: Насонова ВА, Бунчук НВ, редакторы. Избранные лекции по клинической ревматологии. Москва: Медицина; 2001. С. 112-132 [Vasil'ev VI, Simonova MV, Safonova TN. Criteria for the diagnosis of Sjogren's disease and syndrome. In: Nasonova VA, Bunchuk NV, editors. Izbrannye lektsii po klinicheskoi revmatologii (Selected lectures on clinical rheumatology). Moscow: Meditsina; 2001. P. 112-132]. 12. Лапин СВ, Тотолян АА. Иммунологическая лабораторная диагностика аутоимунных заболеваний. Санкт-Петербург: Человек; 2010. 272 с. [Lapin SV, Totolyan AA. Immunologicheskaya laboratornaya diagnostika autoimunnykh zabolevanii (Immunological laboratory diagnostics of autoimmune diseases). Sankt-Peterburg: Chelovek; 2010. 272 p.]. 13. Sung Bin Cho, Keun Jae Ahn, Do Hee Kim, et al. Identification of HnRNP-A2/B1 as a Target Antigen of Anti-Endothelial Cell IgA Antibody in Behchet's Disease. J Invest Dermatol. 2012;132:601-8. doi: 10.1038/jid.2011.397